Evotec and LEO Pharma partner for hit identification platform use

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/krtichanut)
(Image: Getty/krtichanut)

Related tags: Drug discovery, alliance, Partnership, ADME, preclinical, Preclinical contract research, Drug development, Technology

Evotec to use its hit identification platform in LEO Pharma alliance, another drug discovery partnership among the many.

The collaboration will pair Evotec’s hit identification platform with LEO Pharma’s dermatology expertise in an aim to generate new leads against targets for a range of dermatological conditions.

A joint team of scientists from both Evotec and LEO Pharma will have access to Evotec’s high-value drug development and discovery absorption, distribution, metabolism, and excretion (ADME)-Tox services along with the company’s identification platform.

Evotec’s identification platform, according to the company, can be used through multiple platforms including virtual, biochemical, biophysical, and cell and phenotypic based screening with high-throughput capabilities.

Almirall​, a skin-health focused pharmaceutical company, previously collaborated with Evotec to use the platform in a preclinical and drug discovery partnership.

At the time, Dr. Cord Dohrmann, chief scientific officer of Evotec said that the platform “enables disruption of cell signaling via a new approach that has been identified and developed by Evotec scientists in Toulouse and is expected to deliver many more drug discovery opportunities.”

Those drug discovery opportunities led to multiple collaborations. In October, Evotec used its drug discovery and development technology platform after entering an agreement with Sanofi​ to work on early-stage translational projects.

Stealth BioTherapeutics also tapped Evotec​ to conduct its preclinical and toxicology/safety studies for its lead candidate. 

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more